BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/23/2022 10:13:16 AM | Browse: 674 | Download: 1658
 |
Received |
|
2022-03-09 12:11 |
|
Peer-Review Started |
|
2022-03-09 12:13 |
|
First Decision by Editorial Office Director |
|
2022-04-11 21:19 |
|
Return for Revision |
|
2022-04-11 21:19 |
|
Revised |
|
2022-04-30 05:42 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-08-15 06:44 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-08-16 18:37 |
|
Articles in Press |
|
2022-08-16 18:37 |
|
Edit the Manuscript by Language Editor |
|
2022-09-07 12:58 |
|
Typeset the Manuscript |
|
2022-09-15 08:35 |
|
Publish the Manuscript Online |
|
2022-09-23 10:13 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Review |
| Article Title |
Deciphering the role of transforming growth factor-beta 1 as a diagnostic-prognostic-therapeutic candidate against hepatocellular carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Aswathy R Devan, Keechilat Pavithran, Bhagyalakshmi Nair, Maneesha Murali and Lekshmi R Nath |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Amrita Vishwa Vidyapeetham SEED grant |
K-PHAR-22-662 |
|
| Corresponding Author |
Lekshmi R Nath, PhD, Assistant Professor, Department of Pharmacognosy, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Ponekkara, Kochi 682041, Kerala, India. lekshmirnath@aims.amrita.edu |
| Key Words |
Transforming growth factor-beta 1; Inflammation; Immunosuppression; Fibrogenesis; Hepatocellular carcinoma; Biomarker; Immunotherapy |
| Core Tip |
Transforming growth factor-beta 1 (TGF-β1) exhibits a progressive elevation throughout hepatic dysfunction starting from hepatitis to hepatocellular carcinoma (HCC) as an inflammatory cytokine, pro-fibrogenic marker, immunosuppressive agent and pro-carcinogenic growth factor. Aberrant TGF-β1 activation in HCC is associated with poor prognosis and survival. TGF-β1 mediated immunosuppression disturbs the anticancer surveillance and the efficacy of the immunotherapeutic agent. This pleiotropic effect of TGF-β1 in the context of HCC makes it ideal as a diagnostic, prognostic, and therapeutic candidate in HCC. |
| Publish Date |
2022-09-23 10:13 |
| Citation |
Devan AR, Pavithran K, Nair B, Murali M, Nath LR. Deciphering the role of transforming growth factor-beta 1 as a diagnostic-prognostic-therapeutic candidate against hepatocellular carcinoma. World J Gastroenterol 2022; 28(36): 5250-5264 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i36/5250.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i36.5250 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
